Single-agent immunotherapy has improved outcomes for patients with cancer, but only a minority of patients respond, necessitating investigation of combinations of immunotherapy agents. In this issue of Cancer Immunology Research, Milling and colleagues show that neoadjuvant therapy with an intratumoral stimulator of interferon genes agonist combined with systemic IL2 and anti–PD-1 results in clearance of lung metastases mediated by natural killer cells in mouse models of triple-negative breast cancer.

See related article by Milling et al., p. 26. (4).